# US 2011/0182901 A1 · Full length large t tumor antigen of merkel cell polyomavirus as a therapeutic target in merkel cell carcinoma

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0182901 A1
- Document ID: US20110182901A1
- Status: Published application
- Kind: A1
- Application number: 13/004,158
- Filed: 2011-01-11
- Published: 2011-07-28
- Earliest claimed: 2010-01-26
- Assignees: Institut Curie
- Inventors: Martine PETER; Xavier SASTRE-GARAU
- Web page: https://patentgrep.com/patent/US20110182901A1

## CPC

- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61P 31/20: for DNA viruses
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- C07K 14/005: from viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12Q 1/701: {Specific hybridization probes}
- G01N 33/5751: of the skin, e.g. melanoma
- C12N 2710/22021: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2710/22022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2710/22023: Virus like particles [VLP]
- G01N 2333/01: DNA viruses
- G01N 2500/02: Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- Y10T 436/143333: Saccharide [e.g., DNA, etc.]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

The invention relates to a full length Large T tumor antigen of Merkel Cell Polyomavirus (MCV) as a therapeutic target in Merkel Cell Carcinoma (MCC).

## Claims

### Claim 1

A virus-like particle (VLP) wherein said VLP is a polyomavirus comprising a nucleic acid sequence having at least 60% identity with SEQ ID NO:5 (exon 2 of large T antigen, LT) and wherein said VLP has been isolated from a patient, preferably a patient suffering from Merkel Cell Carcinoma (MCC) in an episomal form or integrated in the patient's genome.

### Claim 2 (depends on 1)

A VLP according to claim 1 comprising a polypeptide of at least 470 amino acids having at least 60% identity with SEQ ID NO:6 (LT) over said at least 470 amino acids.

### Claim 3 (depends on 2)

A VLP according to claim 2 comprising a polypeptide having at least 60% identity with SEQ ID NO:6.

### Claim 4 (depends on 1)

A VLP according to claim 1, further comprising at least one nucleic acid selected from the group consisting of the nucleic acids having:
at least 99.4% identity with SEQ ID NO: 5 (exon 2 of LT);
at least 99.2% identity with SEQ ID NO:4 (exon 1 of LT);
at least 99.5% identity with SEQ ID NO:2 (ST);
at least 99.5% identity with SEQ ID NO:7 (VP1);
at least 99.5% identity with SEQ ID NO:9 (VP2);
at least 99.5% identity with SEQ ID NO:11 (VP3) and
at least 99.4% identity with SEQ ID NO:1 (full genome of MCV-IC13).

### Claim 5

An isolated nucleic acid selected from the group consisting of a nucleic acid having at least 99.4% identity with SEQ ID NO:1, a nucleic acid having at least 99.5% identity with SEQ ID NO:2, a nucleic acid having at least 99.2% identity with SEQ ID NO:4, a nucleic acid having at least 99.4% identity with SEQ ID NO:5, a nucleic acid having at least 99.5% identity with SEQ ID NO:7, a nucleic acid having at least 99.5% identity with SEQ ID NO:9 and a nucleic acid having at least 99.5% identity with SEQ ID NO:11.

### Claim 6

A isolated polypeptide selected from the group consisting of an amino acid sequence having at least 99.6% identity with SEQ ID NO:3, an amino acid sequence having at least 98.6% identity with SEQ ID NO:6, an amino acid sequence having at least 99.4% identity with SEQ ID NO:8, an amino acid sequence having at least 99.3% identity with SEQ ID NO:10 and an amino acid sequence having at least 99.0% identity with SEQ ID NO:12, or a fragment of said polypeptide having at least 99.6% identity with the corresponding fragments of SEQ ID NO:3, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10 and SEQ ID NO:12, respectively.

### Claim 7 (depends on 5)

An anti-MCV agent wherein said anti-MCV agent is a molecule which specifically interacts with a nucleic acid according to claim 5.

### Claim 8 (depends on 5)

An anti-MCV agent wherein said anti-MCV agent inhibits the expression and/or the activity of at least one nucleic acid according to claim 5.

### Claim 9

An antibody which specifically recognizes the non-truncated LT protein.

### Claim 10 (depends on 9)

An antibody according to claim 9, wherein said antibody specifically recognizes an antigen comprised between amino acids 456 to 817 of SEQ ID NO: 6.

### Claim 11 (depends on 9)

An antibody according to claim 9, wherein said antibody specifically recognizes a conformational epitope wherein said conformational epitope is partly comprised of residues located between amino acids 456 to 817 of SEQ ID NO: 6.

### Claim 12 (depends on 1)

A method for detecting a VLP according to claim 1, comprising the step of detecting a nucleic acid selected from the group consisting of a nucleic acid having at least 99.4% identity with SEQ ID NO:1, a nucleic acid having at least 99.5% identity with SEQ ID NO:2, a nucleic acid having at least 99.2% identity with SEQ ID NO:4, a nucleic acid having at least 99.4% identity with SEQ ID NO:5, a nucleic acid having at least 99.5% identity with SEQ ID NO:7, a nucleic acid having at least 99.5% identity with SEQ ID NO:9 and a nucleic acid having at least 99.5% identity with SEQ ID NO:11; or detecting a polypeptide selected from the group consisting of an amino acid sequence having at least 99.6% identity with SEQ ID NO:3, an amino acid sequence having at least 98.6% identity with SEQ ID NO:6, an amino acid sequence having at least 99.4% identity with SEQ ID NO:8, an amino acid sequence having at least 99.3% identity with SEQ ID NO:10 and an amino acid sequence having at least 99.0% identity with SEQ ID NO:12, or a fragment of said polypeptide having at least 99.6% identity with the corresponding fragments of SEQ ID NO:3, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10 and SEQ ID NO:12, respectively.

### Claim 13 (depends on 12)

A method according to claim 12, comprising the step of detecting an LT protein with an antibody which specifically recognizes the non-truncated LT protein.

### Claim 14 (depends on 1)

A method for predicting the risk of developing an MCV-associated disease in a patient comprising the step of detecting a VLP according to claim 1 in a tissue sample obtained from said patient.

### Claim 15 (depends on 1)

A method for diagnosing an MCV-associated disease in a patient comprising the step of detecting a VLP according to claim 1 in a tissue sample obtained from said patient.

### Claim 16 (depends on 14)

A method according to claim 14, wherein said MCV-associated disease is Merkel Cell Carcinoma (MCC).

### Claim 17 (depends on 7)

A kit for diagnosis an MCV-associated disease in a patient comprising an anti-MCV agent according to claim 7 and means for revealing said anti-MCV agent or antibody.

### Claim 18 (depends on 6)

A method for identifying an agent that attenuates MCV infection comprising the step of exposing a target DNA to a polypeptide according to claim 6 in the presence or absence of a test compound.

### Claim 19

A pharmaceutical composition comprising:
a VLP according to and/or
a nucleic acid selected from the group consisting of a nucleic acid having at least 99.4% identity with SEQ ID NO:1, a nucleic acid having at least 99.5% identity with SEQ ID NO:2, a nucleic acid having at least 99.2% identity with SEQ ID NO:4, a nucleic acid having at least 99.4% identity with SEQ ID NO:5, a nucleic acid having at least 99.5% identity with SEQ ID NO:7, a nucleic acid having at least 99.5% identity with SEQ ID NO:9 and a nucleic acid having at least 99.5% identity with SEQ ID NO:11 and/or
a polypeptide selected from the group consisting of an amino acid sequence having at least 99.6% identity with SEQ ID NO:3, an amino acid sequence having at least 98.6% identity with SEQ ID NO:6, an amino acid sequence having at least 99.4% identity with SEQ ID NO:8, an amino acid sequence having at least 99.3% identity with SEQ ID NO:10 and an amino acid sequence having at least 99.0% identity with SEQ ID NO:12, or a fragment of said polypeptide having at least 99.6% identity with the corresponding fragments of SEQ ID NO:3, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10 and SEQ ID NO:12, respectively and/or
an anti-MCV agent which is a molecule which specifically interacts with a nucleic acid selected from the group consisting of a nucleic acid having at least 99.4% identity with SEQ ID NO:1, a nucleic acid having at least 99.5% identity with SEQ ID NO:2, a nucleic acid having at least 99.2% identity with SEQ ID NO:4, a nucleic acid having at least 99.4% identity with SEQ ID NO:5, a nucleic acid having at least 99.5% identity with SEQ ID NO:7, a nucleic acid having at least 99.5% identity with SEQ ID NO:9 and a nucleic acid having at least 99.5% identity with SEQ ID NO:11, or specifically interacts with a polypeptide selected from the group consisting of an amino acid sequence having at least 99.6% identity with SEQ ID NO:3, an amino acid sequence having at least 98.6% identity with SEQ ID NO:6, an amino acid sequence having at least 99.4% identity with SEQ ID NO:8, an amino acid sequence having at least 99.3% identity with SEQ ID NO:10 and an amino acid sequence having at least 99.0% identity with SEQ ID NO:12, or a fragment of said polypeptide having at least 99.6% identity with the corresponding fragments of SEQ ID NO:3, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10 and SEQ ID NO:12, respectively and a pharmaceutically acceptable carrier.
